Axastrol (anastrozolum) coated tablets 1 mg. №28

$226.20

Manufacturer: Cyprus

Axastrol (anastrozole) is used for the treatment of early-stage and advanced hormone receptor-positive breast cancer in postmenopausal women.

Category:

Description

Ingredients

active substance: anastrozole;

1 tablet contains 1 mg anastrozole;

excipients: lactose, monohydrate; corn starch; povidone K-30; cellulose microcrystalline; sodium starch glycolate (type A); silicon dioxide colloidal anhydrous; magnesium stearate; talc;

shell: hypromellose, macrogol 400, titanium dioxide (E 171), talc.

Dosage form

Film-coated tablets.

Basic physical and chemical properties: white, round, film-coated tablets with a diameter of approximately 6.6 mm.

Pharmacotherapeutic group

Hormone antagonists and similar agents. aromatase inhibitors.

ATX code L02B G03.

Pharmacodynamics

Axastrol (anastrozole) is a potent, highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is mainly produced by converting androstenedione to estrone by the aromatase enzyme in peripheral tissues. Estrone is further converted to estradiol.

Reducing the level of circulating estradiol has a therapeutic effect in women with breast cancer. In postmenopausal women, taking anastrozole at a daily dose of 1 mg leads to a decrease in estradiol levels by 80%.

Anastrozole has no progestogenic and androgenic activity; in daily doses up to 10 mg does not affect the secretion of cortisol and aldosterone, measured before and after the standard adrenocorticotropic hormone (ACTH) stimulation test. Thus, there is no need for corticosteroid replacement.

Indications

  • adjuvant treatment of early-stage hormone receptor-positive invasive breast cancer in postmenopausal women;
  • adjuvant treatment of early-stage hormone receptor-positive invasive breast cancer in postmenopausal women who have been treated adjuvantly with tamoxifen for 2–3 years;
  • treatment of advanced hormone receptor-positive breast cancer in postmenopausal women.

Contraindications

  • known hypersensitivity to anastrozole or to any component of Axastrol (anastrozole);
  • period of pregnancy or lactation.

Special precautions.

Any unused medicinal products or waste must be disposed of in accordance with local regulations.

Dosage and administration

Axastrol (anastrozole) is taken orally.

The recommended dose for adults, including elderly women, is 1 tablet (1 mg) 1 time per day.

In postmenopausal women with early-stage hormone receptor-positive invasive breast cancer, the recommended duration of adjuvant endocrine treatment is 5 years.

Renal failure. Patients with mild or moderate renal impairment do not require dose adjustment. The use of the drug in patients with severely impaired renal function requires caution.

Liver failure. Patients with mild liver disease dose adjustment is not required. In patients with moderate and severe hepatic impairment, the drug should be used with caution.